MedTrace Logo

Incretin Effect on the Immunological Phenotype

NCT01782261 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-10-11

No results posted yet for this study

Summary

Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes

Conditions

Interventions

DRUG

Liraglutide

once daily subcutaneous injection

DRUG

Saxagliptin

once daily tablet

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Thomas R Pieber, Professor · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782261 on ClinicalTrials.gov